Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -13.01% is 36% above its 4-year average of -20.43%, near the high end of its 4-year range (-30.58%–-10.73%).
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-07-04): -4.64%.
RETURN ON ASSETS (ROA)
-13.01%
RETURN ON ASSETS (ROA) AVG TTM
N/A
RETURN ON ASSETS (ROA) AVG 3Y
-24.53%
RETURN ON ASSETS (ROA) AVG 5Y
-20.43%
RETURN ON ASSETS (ROA) AVG 10Y
-23.61%
RETURN ON ASSETS (ROA) AVG 15Y
-12.75%
RETURN ON ASSETS (ROA) AVG 20Y
-12.99%
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+46.96%
CURRENT VS 5Y AVG
+36.33%
CURRENT VS 10Y AVG
+44.90%
CURRENT VS 15Y AVG
-2.03%
CURRENT VS 20Y AVG
-0.13%
SECTOR MEDIAN · HEALTHCARE
-31.88%
median of 840 covered companies
CURRENT VS SECTOR MEDIAN
+59.18%
vs the sector median at left
IRIDEX Corporation
Market Cap
$12.19M
Return on Assets (ROA)
-13.01%
TTM Avg
N/A
3Y Avg
-24.53%
5Y Avg
-20.43%
Market Cap
$12.28M
Return on Assets (ROA)
-216.84%
TTM Avg
-118.20%
3Y Avg
-6127.40%
5Y Avg
-4092.56%
Market Cap
$12.54M
Return on Assets (ROA)
-420.14%
TTM Avg
-127.99%
3Y Avg
-97.65%
5Y Avg
-85.48%
Market Cap
$12.57M
Return on Assets (ROA)
-49.12%
TTM Avg
-29.80%
3Y Avg
-67.98%
5Y Avg
-117.36%
Market Cap
$12.69M
Return on Assets (ROA)
-77.94%
TTM Avg
-178.68%
3Y Avg
-1009.31%
5Y Avg
-2782.57%
Market Cap
$12.66M
Return on Assets (ROA)
-47.98%
TTM Avg
-31.15%
3Y Avg
-42.27%
5Y Avg
-34.21%
Market Cap
$11.56M
Return on Assets (ROA)
-90.19%
TTM Avg
-82.55%
3Y Avg
-92.57%
5Y Avg
-79.83%
Market Cap
$12.54M
Return on Assets (ROA)
-60.93%
TTM Avg
-160.25%
3Y Avg
-205.49%
5Y Avg
-152.09%
Market Cap
$12.95M
Return on Assets (ROA)
-143.44%
TTM Avg
-68.17%
3Y Avg
-65.00%
5Y Avg
-57.74%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IRIDEX Corporation (IRIX) | $12.19M | -13.01% | N/A | -24.53% | -20.43% |
| Lantern Pharma Inc. (LTRN)vs › | $12.28M | -216.84% | -118.20% | -6127.40% | -4092.56% |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.54M | -420.14% | -127.99% | -97.65% | -85.48% |
| Dare Bioscience, Inc. (DARE)vs › | $12.57M | -49.12% | -29.80% | -67.98% | -117.36% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.69M | -77.94% | -178.68% | -1009.31% | -2782.57% |
| Cytosorbents Corporation (CTSO)vs › | $12.66M | -47.98% | -31.15% | -42.27% | -34.21% |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.56M | -90.19% | -82.55% | -92.57% | -79.83% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.54M | -60.93% | -160.25% | -205.49% | -152.09% |
| Passage Bio, Inc. (PASG)vs › | $12.95M | -143.44% | -68.17% | -65.00% | -57.74% |
| Biofrontera Inc. (BFRI)vs › | $11.43M | -26.45% | -58.62% | -47.64% | -51.16% |
ROA
-13.0%
ROE
-97.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-01-03 | -15.22% |
| 2024-12-31 | -30.58% |
| 2023-12-31 | -27.79% |
| 2022-12-31 | -17.85% |
| 2021-12-31 | -10.73% |
| 2020-12-31 | -22.63% |
| 2019-12-31 | -25.32% |
| 2018-12-31 | -30.75% |
| 2017-12-31 | -30.90% |
| 2016-12-31 | -24.33% |
| 2015-12-31 | 1.13% |
| 2014-12-31 | 24.00% |
| 2013-12-31 | 6.62% |
| 2012-12-31 | 4.97% |
| 2011-12-31 | 8.12% |
| 2010-12-31 | 10.42% |
| 2009-12-31 | 9.14% |
| 2008-12-31 | -26.11% |
| 2007-12-31 | -47.74% |
| 2006-12-31 | -14.32% |
| 2005-12-31 | 4.07% |
| 2004-12-31 | -1.03% |
| 2003-12-31 | 1.04% |
| 2002-12-31 | 0.44% |
| 2001-12-31 | -3.77% |
| 2000-12-31 | 6.90% |
| 1999-12-31 | 4.95% |
| 1998-12-31 | 5.99% |
| 1997-12-31 | 7.87% |
| 1996-12-31 | 4.22% |
